This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
—Apparently, Dr Ross-Degnan and his colleagues misunderstood what I had said in my Editorial. My point was that the FDA could not take into account the risks posed by substituted products before making a decision to withdraw a drug from the market, not that such risks would prevent the FDA from educating clinicians regarding optimal substitute drugs. I have no quarrel with the FDA attempting to identify the appropriate clinicians and educating them in regard to the risk of such substituted products, although this would be complex and require considerable resources. Nonetheless, we must look for various ways of educating such practitioners and I agree with the suggestions made in their letter.
Goyan JE. Withdrawal of a Drug From the Market: What Should the Prescriber Do?-Reply. JAMA. 1994;272(16):1253. doi:10.1001/jama.1994.03520160037030